Featured Programs
Illuccix® and PSMA Imaging for the Initial Staging of Prostate Cancer
Presented by: Umesh Oza, MD  |  Naveen Kella, MD
Prostate Cancer Training

In this program, Dr. Umesh Oza and Dr. Naveen Kella discuss the use of 68Ga-PSMA-11 for effective prostate cancer staging. This webinar is designed for clinicians seeking to enhance their understanding of PSMA imaging in the context of prostate cancer management. Key topics include differentiating the benefits of gallium-based PSMA imaging compared to conventional methods for detecting suspected metastatic disease. The session will also feature patient case studies to analyze the real-world effectiveness of Illuccix.

Brain Tumor Imaging Using Amino Acid PET
Presented by: Prof. Dr. Karl-Josef Langen, MD
Brain Tumor Imaging Using Amino Acid PET

This program is designed with the following educational objectives:

  1. Review of uptake mechanisms of amino acid tracers and the additional information provided by amino acid PET in relation to conventional MRI.
  2. Deliver insights into the clinical benefits of FET PET in the assessment of newly diagnosed brain tumors.
  3. Describe the use of FET PET in the differentiation of tumor progression and treatment-related changes in pretreated gliomas and brain metastases.
  4. Explain the advantages of FET PET in treatment monitoring of cerebral gliomas.
Reader Training

Reader Training is an educational resource from Telix Pharmaceuticals, makers of Illuccix® (kit for the preparation of gallium Ga 68 gozetotide Injection), designed to improve PSMA-11 PET/CT reader skills and increase confidence in identifying pathology while following guidelines to optimize PET/CT reading. Learning modules will include, learning objectives, case study reviews and teaching points presented with video, slides, supporting resources and clinical articles.

Reader Training - Modules 1, 2 and 3
Module 1 - Parts One & Two:
The Basics of 68Ga PSMA-11 PET/CT
Presented by: Nat Lenzo, MD
Module 2:
Considerations for 68Ga-PSMA-11 PET/CT Imaging Interpretation
Presented by: Jaideep S. Sohi, MD
Module 3 - Parts One, Two & Three:
Advanced Reading Skills: A Comprehensive PSMA-11 PET/CT Case Study Review
Presented by: Stefano Fanti, MD and Andrea Farolfi, MD
Featured Case of The Month
PSMA PET CT in Prostate Cancer
Presented by: Jaideep S. Sohi, MD • American Molecular Imaging, Inc.
Combination Therapy Improves Efficacy in Widespread Prostate Metastatic Disease

History: Patient is a 72-year-old male with history of prostate carcinoma, diagnosed in 2020. Gleason 4+3 =7. Status post radiation therapy, ADT and Lu-PSMA therapy. Presents now with rising PSA values, most recently at 5.6 ng/dl.

Other Educational Resources

The content in this section links to third-party websites. Therefore, to view these educational resources, you will be be leaving TelixU and redirected to another website

Disclaimer: Telix is proud to sponsor this educational article by Applied Radiology®, however, Telix did not participate in the creation of this educational content and is not responsible for any content on or the privacy practices of third-party sites.

Applied Radiology
Not All Prostate-Specific Membrane Antigen Imaging Agents Are Created Equal: Diagnostic Accuracy of Ga-68 PSMA-11 PET/CT for Initial and Recurrent Prostate Cancer

Disclaimer: Telix is proud to sponsor this educational series with Urology Times®, however, Telix did not participate in the creation of this educational content and is not responsible for any content on or the privacy practices of third-party sites.

Urology Times
Clinical Updates on PSMA-PET Imaging for Prostate Cancer

Key opinion leaders discuss the latest PSMA-PET imaging updates for prostate cancer and consider how real-world practice has evolved.